newsfilter
← Latest News
Business Wire·

Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer

  • Mirum Pharmaceuticals appointed Rob Myers, M.D. as Chief Medical Officer effective September 21, 2026, to lead global medical & clinical development functions.
  • Dr. Myers brings over two decades of experience, including 200+ peer-reviewed publications, with expertise in hepatology, primary sclerosing cholangitis, metabolism, & endocrine disorders.
  • He joins from OrsoBio where he served as Chief Medical Officer & Head of Development, having previously held senior roles at Gilead Sciences overseeing liver fibrosis & cholestatic disease programs.
  • CEO Chris Peetz stated Dr. Myers' liver disease expertise aligns with Mirum's expected commercial growth & diverse late-stage pipeline.
  • Dr. Myers expressed excitement to advance medicines for rare disease patients at this critical growth stage for the company.
  • Joanne Quan, M.D. is departing Mirum, & the company thanked her for her leadership & contributions.
  • Mirum's current commercial portfolio includes LIVMARLI® for Alagille syndrome & PFIC, CHOLBAM® for bile-acid synthesis disorders, & CTEXLI® for cerebrotendinous xanthomatosis.
  • The clinical pipeline features volixibat for PSC & PBC, brelovitug for chronic hepatitis delta virus, zilurgisertib for FOP, & MRM-3379 for Fragile X syndrome.